# Global Sarcoma Therapy Now Available in Thailand

- Link: https://www.thailand-business-news.com/pr-news/global-sarcoma-therapy-now-available-in-thailand
- Published: 2026-11-16T04:00:00+07:00
- Author: PR Newswire

|   |

 1. _Approval of YONDELIS^(®) (trabectedin) by the Thai FDA for patients who have failed
    prior treatment with anthracyclines and ifosfamide or for those who are unsuited
    to receive these agents^(1)_
 2. _YONDELIS provides an additional treatment option for Thai adults diagnosed with
    advanced soft tissue sarcoma _
 3. _Eligible adult patients in Thailand with advanced soft tissue sarcoma will have
    access to YONDELIS from 1^(st) December 2026_

SINGAPORE, Nov. 16, 2026 /PRNewswire/ — Independent biopharmaceutical company Specialised
Therapeutics announced that the Thailand Food and Drug Administration approved YONDELIS
^(®) (trabectedin) on 24 July 2026 for the treatment of adult patients with advanced
soft tissue sarcoma (STS).^(1)

The regulatory approval grants access to YONDELIS for patients who have failed prior
treatment with anthracyclines and ifosfamide, or for those who are unsuited to receive
these agents.^(1) The approval is based on the clinical efficacy and safety data
from the Phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which
evaluated YONDELIS versus the chemotherapy agent dacarbazine in patients with unresectable
or metastatic liposarcoma or leiomyosarcoma previously treated with an anthracycline
and at least one additional chemotherapy regimen.^(2,3)

In the pivotal Phase 3 clinical trial, patients treated with YONDELIS achieved a
statistically significant improvement in median progression-free survival (PFS) 
of 4.2 months versus 1.5 months for trabectedin vs dacarbazine HR, 0.55; _p_<0.001,
representing a 45% reduction in the risk of disease progression or death.^(2)

YONDELIS demonstrated a manageable safety profile, with severe (Grade 3 or 4) adverse
reactions occurring in less than one-third of patients. The most common adverse 
reactions of any severity grade included neutropenia, nausea, vomiting, elevated
liver enzymes (AST/ALT), anaemia, fatigue, thrombocytopenia, decreased appetite,
and diarrhoea.^(1,2)

YONDELIS is an established antineoplastic agent originally derived from the sea 
squirt (_Ecteinascidia turbinata_). It exerts the anti-tumor effect by binding to
the minor groove of DNA, disrupting the cell cycle and preventing cancer cells from
multiplying.^(4)

STS is a rare and complex disease. In Thailand, the age-standardized incidence rate
of STS is 2.14 per 100,000 person-years, which is relatively low compared to Western
nations. The most frequently reported histological subtypes among Thai patients 
are unspecified sarcoma (24.8%), leiomyosarcoma (19.0%), and liposarcoma (11.4%).
While current healthcare treatments yield a five-year relative survival rate of 
62.6% for soft tissue sarcoma in Thailand, there remains a critical need for advanced,
specialised therapies for patients whose cancer progresses or relapses after initial
care.^(5)

**Carlo Montagner, CEO, Specialised Therapeutics, commented:**

_"The approval of YONDELIS in Thailand expands access to a recognized, international
standard-of-care therapy for patients living with advanced STS. STS remains a complex
disease with limited treatment options once initial therapies fail. Securing regulatory
approval in Thailand aligns with our core mission to address unmet medical needs
and deliver specialised oncology therapies across South East Asia."_

Under an exclusive licensing agreement with global partner PharmaMar S.A., Specialised
Therapeutics will be responsible for all regulatory, commercialisation, distribution,
and medical engagement operations for YONDELIS in Thailand.

**About Specialised Therapeutics**

Specialised Therapeutics (ST) is an international biopharmaceutical company dedicated
to commercializing novel, high-value therapies and diagnostic technologies across
Australia, New Zealand, and South East Asia. ST collaborates with leading global
biopharmaceutical partners to deliver healthcare solutions where there is an unmet
clinical need. For additional information, visit [www.stbiopharma.com](https://stabiopharma.com/).

**About PharmaMar**

Headquartered in Spain, PharmaMar is a biopharmaceutical company focused on the 
research and development of new oncology treatments, whose mission is to improve
the healthcare outcomes of patients afflicted by serious diseases with our innovative
medicines. The Company is inspired by the sea, driven by science, and motivated 
by patients with serious diseases to improve their lives by delivering novel medicines
to them. PharmaMar intends to continue to be the world leader in marine medicinal
discovery, development and innovation.

For more information, please visit: [www.pharmamar.com](http://www.pharmamar.com/)

**About YONDELIS**^(®) **(trabectedin)**

Yondelis^(®) (trabectedin) is a novel, synthetically produced antitumor agent originally
isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis^(®) exerts
its anticancer effects primarily by inhibiting active transcription, a type of gene
expression on which proliferating cancer cells are particularly dependent.^(6)

**Important Safety Information on YONDELIS**

YONDELIS is contraindicated in patients with concurrent serious or uncontrolled 
infections. Patients who develop a fever should promptly seek medical attention 
so active supportive therapy can be started immediately. Women of childbearing potential
must use highly effective contraception during treatment and 8 months thereafter
and immediately inform the treating physician if a pregnancy occurs. Men of fertile
age must use highly effective contraception during treatment and 5 months after 
treatment.^(1,2)

In clinical trials, the most common adverse reactions of any severity grade were
neutropenia, nausea, vomiting, increased liver enzymes (AST/ALT), anaemia, fatigue,
thrombocytopenia, anorexia, and diarrhoea. Less than one-third of patients experienced
serious adverse reactions of Grade 3 or 4 severity. Fatal adverse reactions occurred
in 1.9% of patients and were often the result of combined events including pancytopenia,
febrile neutropenia, sepsis, hepatic involvement, multiorgan failure, and rhabdomyolysis.
^(2)

Treatment with YONDELIS can cause severe myelosuppression, including Grade 3 or 
4 neutropenia and thrombocytopenia. A full blood cell count including differential
and platelet count must be performed at baseline, weekly for the first two cycles,
and then once between cycles. Liver function tests and creatinine clearance must
also be closely monitored prior to and during treatment to manage the risks of hepatotoxicity
and renal impairment.

YONDELIS is a prescription medicine and can only be prescribed by a doctor. For 
more information about YONDELIS, or advanced STS, please see your health care professional.

  |

**References**

  |  
 |

1. YONDELIS^(®) (trabectedin) Thai FDA Product Information. ([Link](https://pertento.fda.moph.go.th/FDA_INFORMATION_DRUG/Home/Public_Information_Drug?Newcode=U1DR1C1012690033211C))

  |  
 |

2. Demetri GD, von Mehren M, Jones RL, et al. _J Clin Oncol._ 2016; 34(8):786-793.

  |  
 |

3. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. Version 5.2026

  |  
 |

4. D’Incalci M, Galmarini CM. _Mol Cancer Thera_ 2010; 9(8): 2157-2163.

  |  
 |

5. Klangjorhor J, Pongnikorn D, Sittiju P et al. _Scientific Reports _2022; 12:12824

  |  
 |

6. Brodowicz T. Trabectedin in Soft Tissue Sarcoma. Future Oncol. 2014; 10(8):1–5

  |

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Global Sarcoma Therapy Now Available in Thailand ](https://en.prnasia.com/story/archive/5097065_CN97065_0?rand=184833)
